MX2020006529A - Composiciones de lisofosfatidilcolina. - Google Patents

Composiciones de lisofosfatidilcolina.

Info

Publication number
MX2020006529A
MX2020006529A MX2020006529A MX2020006529A MX2020006529A MX 2020006529 A MX2020006529 A MX 2020006529A MX 2020006529 A MX2020006529 A MX 2020006529A MX 2020006529 A MX2020006529 A MX 2020006529A MX 2020006529 A MX2020006529 A MX 2020006529A
Authority
MX
Mexico
Prior art keywords
compositions
lysophosphatidylcholine compositions
lysophosphatidylcholine
marine lysophosphatidylcholine
nutraceuticals
Prior art date
Application number
MX2020006529A
Other languages
English (en)
Inventor
Nils Hoem
Finn Myhren
Petter- Arnt Hals
Armend Håti
Original Assignee
Aker Biomarine Antarctic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aker Biomarine Antarctic As filed Critical Aker Biomarine Antarctic As
Publication of MX2020006529A publication Critical patent/MX2020006529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00—Production of fats or fatty oils from raw materials
    • C11B1/02—Pretreatment
    • C11B1/025—Pretreatment by enzymes or microorganisms, living or dead
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/184—Emulsifier
    • A23V2250/1846—Phosphatidyl Choline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/1882—Polyunsaturated fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)

Abstract

La presente invención proporciona composiciones de lisofosfatidilcolina marina para el uso en productos farmacéuticos, nutracéuticos y alimentos funcionales, así como también en métodos para preparar composiciones de lisofosfatidilcolina marina.
MX2020006529A 2017-12-21 2018-12-21 Composiciones de lisofosfatidilcolina. MX2020006529A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762608891P 2017-12-21 2017-12-21
US201862725683P 2018-08-31 2018-08-31
PCT/IB2018/001588 WO2019123015A1 (en) 2017-12-21 2018-12-21 Lysophosphatidylcholine compositions

Publications (1)

Publication Number Publication Date
MX2020006529A true MX2020006529A (es) 2021-01-08

Family

ID=65685831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006529A MX2020006529A (es) 2017-12-21 2018-12-21 Composiciones de lisofosfatidilcolina.

Country Status (15)

Country Link
US (3) US11065267B2 (es)
EP (1) EP3727037B1 (es)
JP (1) JP7625416B2 (es)
KR (2) KR20240135688A (es)
CN (1) CN111902053A (es)
AU (1) AU2018389595B2 (es)
BR (1) BR112020012705A2 (es)
CA (1) CA3086416A1 (es)
ES (1) ES3052913T3 (es)
IL (1) IL275534B2 (es)
MX (1) MX2020006529A (es)
PL (1) PL3727037T3 (es)
PT (1) PT3727037T (es)
SG (1) SG11202005905TA (es)
WO (1) WO2019123015A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006529A (es) 2017-12-21 2021-01-08 Aker Biomarine Antarctic As Composiciones de lisofosfatidilcolina.
EP3866781A4 (en) * 2018-10-16 2022-11-09 Systamedic Inc. NOVEL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2020254675A1 (en) 2019-06-20 2020-12-24 Aker Biomarine Antarctic As Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy
NL2023407B1 (en) * 2019-06-28 2021-02-01 Aker Biomarine Antarctic As Parenteral lysophosphatidylcholine formulations
CN110564786B (zh) * 2019-08-02 2022-06-03 大渔华创(广州)海洋生物科技有限公司 一种epa/dha型溶血磷脂组合物及其制备方法
TWI815067B (zh) * 2019-12-26 2023-09-11 日商瑪魯哈日魯股份有限公司 包含結合有多元不飽合脂肪酸之磷脂質之魚卵脂質組成物
JP7599077B2 (ja) * 2020-03-31 2024-12-13 アーケル バイオマリーン ヒューマン イングリーディエンツ エーエス Ｌｐｃ－ｄｈａおよびｌｐｃ－ｅｐａが豊富なクリルオイル組成物
WO2022006711A1 (en) * 2020-07-06 2022-01-13 Kemin Industries, Inc. Method for the preparation of lysophosphatidylinositol
WO2022101678A2 (en) 2020-11-15 2022-05-19 Aker Biomarine Antarctic As Lysophospholipid formulations
WO2022125684A1 (en) * 2020-12-08 2022-06-16 Orochem Technologies Inc. Process for purifying lpc-dha and/or lpc-epa using a chromatographic stationary phase and compositions thereof
WO2024095090A1 (en) 2022-11-01 2024-05-10 Aker Biomarine Antarctic As Phospholipid compositions for delivery of therapeutic compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0657715B2 (ja) * 1987-04-09 1994-08-03 キユーピー株式会社 Ｌｐｃ以外のリゾ型リン脂質をほとんど含まないリゾリン脂質の製造方法
FR2698269B1 (fr) 1992-11-24 1995-01-06 Inst Nat Sante Rech Med Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
CA2587730A1 (en) 2004-11-17 2006-05-26 Natural Asa Enzymatically synthesized marine phospholipids
JP2006197842A (ja) * 2005-01-20 2006-08-03 Shizuoka Prefecture ホスホリパーゼａ１活性を有する組成物、それを用いて得られる２−アシル型リゾリン脂質、及びそれらの製造方法
US20080044487A1 (en) 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
US20080021000A1 (en) 2006-07-19 2008-01-24 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
EP2085089A1 (en) * 2008-02-01 2009-08-05 KTB-Tumorforschungs GmbH Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior
AR071699A1 (es) 2008-05-09 2010-07-07 Kemin Ind Inc Uso de lisofosfolipidos para tratar la inflamacion. composicion.
US9814256B2 (en) * 2009-09-14 2017-11-14 Rimfrost Technologies As Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof
US8906886B2 (en) 2009-07-03 2014-12-09 Su Chen Composition and method for promoting survival of aged basal forebrain cholinergic neuron leading to provention and treatment of age-related neurodegenerative disorder
AU2009354456B2 (en) * 2009-10-30 2014-05-08 Tharos Ltd Solvent-free process for obtaining phospholipids and neutral enriched krill oils
CA2812751C (en) * 2010-09-30 2018-05-01 National University Corporation Tokyo University Of Marine Science And Technology Composition containing 2-acyl-lysophosphatidylserine and method for producing the same
JP6058933B2 (ja) 2012-07-26 2017-01-11 キヤノン株式会社 動画処理装置およびその制御方法、プログラム並びに記憶媒体
AU2013371074B2 (en) 2012-12-24 2018-07-26 Qualitas Health Inc. Eicosapentaenoic acid (EPA) formulations
US10175256B2 (en) 2013-09-26 2019-01-08 National University Of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
WO2015069097A1 (en) 2013-11-08 2015-05-14 N.V. Nutricia Efficacy of dietary dha-phospholipid for brain dha and dpa accretion in neonates
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
US9556116B2 (en) 2015-02-11 2017-01-31 Orochem Technologies, Inc. Krill oil refinery for purification of krill oil extract
WO2016128838A2 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid compositions
JP6763521B2 (ja) 2016-05-23 2020-09-30 国立大学法人北海道大学 ２−ｄｈａ−リゾホスファチジルコリン含有脂質組成物及びその製造方法
BR112019011310A2 (pt) * 2016-12-09 2019-10-15 Balchem Corp nutrientes essenciais e métodos relacionados
US10555957B2 (en) 2017-05-10 2020-02-11 The Board Of Trustees Of The University Of Illinois Methods and compositions for enriching DHA levels in the brain
MX2020006529A (es) 2017-12-21 2021-01-08 Aker Biomarine Antarctic As Composiciones de lisofosfatidilcolina.

Also Published As

Publication number Publication date
JP2021508343A (ja) 2021-03-04
US20250090561A1 (en) 2025-03-20
AU2018389595A1 (en) 2020-07-09
WO2019123015A1 (en) 2019-06-27
SG11202005905TA (en) 2020-07-29
US12076333B2 (en) 2024-09-03
IL275534B2 (en) 2024-09-01
AU2018389595B2 (en) 2024-10-10
ES3052913T3 (en) 2026-01-15
IL275534B1 (en) 2024-05-01
BR112020012705A2 (pt) 2020-11-24
CA3086416A1 (en) 2019-06-27
US11065267B2 (en) 2021-07-20
IL275534A (en) 2020-08-31
EP3727037A1 (en) 2020-10-28
JP7625416B2 (ja) 2025-02-03
PT3727037T (pt) 2025-11-13
PL3727037T3 (pl) 2026-01-19
CN111902053A (zh) 2020-11-06
US20190201424A1 (en) 2019-07-04
KR20200128656A (ko) 2020-11-16
EP3727037B1 (en) 2025-10-08
WO2019123015A8 (en) 2020-08-06
KR20240135688A (ko) 2024-09-11
US20210338697A1 (en) 2021-11-04
KR102704572B1 (ko) 2024-09-06

Similar Documents

Publication Publication Date Title
MX2020006529A (es) Composiciones de lisofosfatidilcolina.
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
MX387665B (es) Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX375352B (es) Reguladores de nrf2.
CR20150462A (es) Inhibidores de erk y sus usos
UY35385A (es) ?métodos y composiciones para el control de malezas?.
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
ECSP16079984A (es) Conservación de productos perecederos a base de biopolímeros
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
WO2016001754A3 (en) Methods for three dimensional reconstruction and determining the quality of an embryo
NZ735362A (en) Lipid compositions
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2018000756A1 (es) Métodos moleculares de aseguramiento de la calidad para su uso en la secuenciación
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CU20160168A7 (es) Proceso para preparar cianhidrinas que contienen fósforo
MX384427B (es) Composiciones de proteína concentrada y métodos para su elaboración y uso.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112017002090A2 (pt) formulação de fator viii
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
CL2018003792A1 (es) Procedimiento para enfriamineto de elementos de madera acetilada.